Cellosaurus logo
expasy logo

Cellosaurus HL-60/RS (CVCL_XE38)

[Text version]
Cell line name HL-60/RS
Accession CVCL_XE38
Resource Identification Initiative To cite this cell line use: HL-60/RS (RRID:CVCL_XE38)
Comments Group: Patented cell line.
Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201430.
Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI_28748; Doxorubicin (Adriablastin; Adriamycin).
Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
Sequence variations
  • Gene deletion; HGNC; HGNC:11998; TP53; Zygosity=Homozygous (from parent cell line).
  • Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line).
  • Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line).
Disease Adult acute myeloid leukemia (NCIt: C9154)
Acute myeloid leukemia (ORDO: Orphanet_519)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0002 (HL-60)
Sex of cell Female
Age at sampling 36Y
Category Cancer cell line
Publications

Patent=CN104004715B
Wei H.-L., Chen J., Cheng J., Xie B., Yi J., Wang B.
Human leukemia HL-60 cell drug-resistance cell line HL-60/RS cell and preparation method thereof.
Patent number CN104004715B, 16-Nov-2016

PubMed=29399180; DOI=10.3892/ol.2017.7353; PMCID=PMC5768105
Chen J., Wei H.-L., Cheng J., Xie B., Wang B., Yi J., Tian B.-Y., Liu Z., Wang F.-F., Zhang Z.-W.
Characteristics of doxorubicin-selected multidrug-resistant human leukemia HL-60 cells with tolerance to arsenic trioxide and contribution of leukemia stem cells.
Oncol. Lett. 15:1255-1262(2018)

Cross-references
Cell line databases/resources cancercelllines; CVCL_XE38
CCRID; 4201PAT-CCTCC00581
Encyclopedic resources Wikidata; Q94211650
Entry history
Entry creation06-Sep-2019
Last entry update19-Dec-2024
Version number11